New smart drug targets tough cancers in first human trial
NCT ID NCT07360314
First seen Jan 23, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study aims to find a safe dose and check for early signs of tumor shrinkage. About 138 participants with cancers like lung, breast, ovarian, head and neck, pancreatic, or stomach cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer - Vancouver - BC Cancer Agency
NOT_YET_RECRUITINGVancouver, Canada
Contact Phone: •••-•••-••••
Contact
-
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center
RECRUITINGHuntersville, North Carolina, 28078, United States
Contact Phone: •••-•••-••••
Contact
-
Hospital Universitari Vall d'Hebron - VHIO - Oncology - Phase I Unit
NOT_YET_RECRUITINGBarcelona, 08035, Spain
Contact
-
NEXT Houston
RECRUITINGGalveston, Texas, 77001, United States
Contact
-
NEXT Madrid - Hospital Universitario Quironsalud Madrid
NOT_YET_RECRUITINGMadrid, Spain
Contact Phone: •••-•••-••••
Contact
-
NEXT Oncology - PARENT
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-••••
Contact
-
National Cancer Center Hospital
RECRUITINGTokyo, Japan
Contact Phone: •••-•••-••••
Contact
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Canada
Contact Phone: •••-•••-••••
Contact
-
Yale University - Yale University School of Medicine
NOT_YET_RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M7437 (an antibody-drug conjugate that delivers a chemotherapy drug directly to cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for several advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) and small study, so the drug may not prove safe or effective. Side effects from the chemotherapy payload are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.